FDA Approvals, Agreements, Investor Conference Schedules, and Technical Updates - Analyst Notes on Covidien, Pacira, Techne, OraSure and Raptor Pharmaceutical

NEW YORK, June 16, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Covidien plc (NYSE: COV), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Techne Corp. (NASDAQ: TECH), OraSure Technologies Inc. (NASDAQ: OSUR) and Raptor Pharmaceutical Corp. (NASDAQ: RPTP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3789-100free.

Covidien plc Analyst Notes
On June 10, 2014, Covidien plc (Covidien) announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Apollo™ Onyx™ delivery micro catheter. According to the Company, the micro catheter is designed to reduce technical challenges of catheter retrieval during Onyx™ LES embolizations of brain arteriovenous malformations (bAVMs) and is the first detachable tip micro catheter available in the U.S. Brett Wall, President, Neurovascular, Covidien, stated, "Covidien is offering a new level of confidence for physicians by providing the only detachable tip micro catheter in the U.S. The Apollo Onyx micro catheter has the potential to improve patient outcomes by safeguarding the neurovasculature during catheter retrieval." Lastly, the Company added that the Apollo Onyx micro catheter will be showcased on July 28, 2014 at the Society of NeuroInterventional Surgery's (SNIS) 11th annual meeting to be held in Colorado Springs, Colorado. The full analyst notes on Covidien are available to download free of charge at:

http://www.analystsreview.com/Jun-17-2014/COV/report.pdf

Pacira Pharmaceuticals Inc. Analyst Notes
On June 12, 2014, Pacira Pharmaceuticals Inc.'s (Pacira) stock decreased by 1.50%, closing at $82.00. Over the past six month trading period, Company stock increased by 66.73% compared to the Nasdaq Composite which went up by 7.48% during the same trading period. The full analyst notes on Pacira are available to download free of charge at:

http://www.analystsreview.com/Jun-17-2014/PCRX/report.pdf

Techne Corp. Analyst Notes
On June 12, 2014, Techne Corp.'s (Techne) stock went up by 0.87%, ending at $88.31. Over the past five day trading period, Company stock increased by 1.37%, compared to the Nasdaq Composite which reflected an increase of 0.03% during the same period. The full analyst notes on Techne are available to download free of charge at:

http://www.analystsreview.com/Jun-17-2014/TECH/report.pdf

OraSure Technologies Inc. Analyst Notes
On June 11, 2014, OraSure Technologies Inc. (OraSure) announced that it has entered into a Master Program Services and Co-Promotion Agreement with AbbVie Inc. under which the companies will co-promote the OraSure's OraQuick® HCV Rapid Test (for testing individuals at-risk for hepatitis C) in the U.S. According to the Company, it has granted exclusive promotion rights to AbbVie for the OraQuick® HCV test in certain markets, along with providing certain additional services in support of HCV testing. Additionally, the Company stated that it will receive up to $75 million in exclusivity payments over the term of the agreement, which runs through December 31, 2019. Commenting on the agreement, Douglas A. Michels, OraSure President and CEO, stated, "This new collaboration allows us to educate healthcare professionals and the patients they treat about hepatitis C and provide them with a very important rapid diagnostic tool." The full analyst notes on OraSure are available to download free of charge at:

http://www.analystsreview.com/Jun-17-2014/OSUR/report.pdf

Raptor Pharmaceutical Corp. Analyst Notes
On June 10, 2014, Raptor Pharmaceutical Corp. (Raptor Pharmaceutical) announced that the Company management will participate in three upcoming investor conferences in June 2014. The Company will participate at the Wells Fargo Healthcare Conference on June 17, 2014 at 8:50 a.m. EDT in Boston and at the JMP Securities Healthcare Conference on June 25, 2014, at 9:30 a.m. EDT to be held in New York. Raptor Pharmaceutical stated that a live audio webcast and archive of both presentations will be made available through Raptor Pharmaceutical's website. The Company added that it will also participate at the Janney Capital Markets Healthcare Corporate Access Day on June 26, 2014, at 8:00 a.m. to 4 p.m. EDT in Boston. The full analyst notes on Raptor Pharmaceutical are available to download free of charge at:

http://www.analystsreview.com/Jun-17-2014/RPTP/report.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.analystsreview.com

SOURCE Analysts Review